Tandem mass spectrometry
This article was originally published in The Gray Sheet
Executive Summary
Pediatrix Medical Group's patent protections "could undermine the public health nature of newborn screening," Johns Hopkins University bioethicist Neil Holtzman, MD, warns in an editorial in the Nov. 19 issue of JAMA. "By charging royalties, Pediatrix could force nonprofit laboratories to either raise their prices or abandon tandem mass spectrometry," he states, noting that in Maryland the company offers screening at a lower price than the public program. Currently, Pediatrix reports positive test results to Maryland's health department, but in the future, the firm could refer infants to physicians within its own practice group, Holtzman cautions. In May, Pediatrix acquired privately held newborn screening lab Neo Gen Screening for $34 mil. (1"The Gray Sheet" May 19, 2003, p. 12)...
You may also be interested in...
Newborn Screening Trends Suggest Expanded Test Menus On Horizon
Pressure from patient organizations and parents are among factors driving an increase in the number of newborn screening tests included in mandatory state screening programs, according to Neo Gen Screening
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.